Soluble epoxide hydrolase inhibition modulates vascular remodeling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 3, 2010, Pages

  Simpkins, A N ^a   Rudic, R D ^a   Roy, S ^a   Tsai, H J ^c   Hammock, B D ^c   Imig, J D ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelium; Epoxyeicosatrienoic acids; Hyperplasia; Hypertension; Hypertrophy; Mice

Indexed keywords

12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; ENZYME INHIBITOR; EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY LIGATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE DELETION; HYPERTENSION; IN VIVO STUDY; INTIMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; VASCULAR SURGERY;

ANIMALS; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; EPOXIDE HYDROLASES; HYPERPLASIA; LAURIC ACIDS; LIGATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TUNICA INTIMA;

EID: 77749279557     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00543.2009     Document Type: Article

References (40)

1. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels. Circulation 107: 769-776, 2003.
2. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
3. Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 51: 567-573, 2008.
4. Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther 316: 815-821, 2006.
5. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 99: 2222-2227, 2002.
6. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842-848, 2005.
7. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JY, Hammock BD, Spector AA. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314: 260-270, 2005.
8. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, Spector AA. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276: 14867-14874, 2001.
9. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
10. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 49: 525-533, 2004.
11. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109: 335-339, 2004.
12. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40: 485-490, 2002.
13. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14: 2829-2837, 2005.
14. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 26: 854-857, 1995.
15. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 37: 529-534, 2001.
16. Huang A, Sun D, Carroll MA, Jiang H, Smith CJ, Connetta JA, Falck JR, Shesely EG, Koller A, Kaley G. EDHF mediates flow-induced dilation in skeletal muscle arterioles of female eNOS-KO mice. Am J Physiol Heart Circ Physiol 280: H2462-H2469, 2001.
17. Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, Kaley G. Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res 96: 376-383, 2005.
18. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50: 3825-3840, 2007.
19. Ibrahim J, Miyashiro JK, Berk BC. Shear stress is differentially regulated among inbred rat strains. Circ Res 92: 1001-1009, 2003.
20. Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 38: 247-255, 2001.
21. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996.
22. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46: 975-981, 2005.
23. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33: 1353-1358, 1999.
24. Klein LW. Atherosclerosis regression, vascular remodeling, and plaque stabilization. J Am Coll Cardiol 49: 271-273, 2007.
25. Korshunov VA, Berk BC. Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined. Circulation 110: 220-226, 2004.
26. Kumar A, Lindner V,. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17: 2238-2244, 1997.
27. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-1649, 2006.
28. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 13: 3480-3487, 2008.
29. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 73: 792-796, 1993.
30. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102: 16747-16752, 2005.
31. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 298: 879-885, 2001.
32. Manhiani M, Quigley J, Knight S, Moore T, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal inflammation and injury in DOCA-salt hypertension (Abstract). Hypertension 50: e89, 2007.
33. Miyashiro JK, Poppa V, Berk BC. Flow-induced vascular remodeling in the rat carotid artery diminishes with age. Circ Res 81: 311-319, 1997.
34. Morisseau C, Hammock BD. Gerry Brooks and epoxide hydrolases: four decades to a phamaceutical. Pest Manag Sci 64: 594-609, 2008.
35. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 26: 2462-2468, 2006.
36. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64: 482-490, 2003.
37. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, Fleming I, Hammock BD, Brandes RP. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 27: 322-331, 2009.
38. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
39. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96: 1240-1247, 2005.
40. Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remo47deling: clinical correlates and experimental links. Am J Hum Genet 64: 673-677, 1999.